Discover how Actinium-225 PSMA therapy works, its current research status, early clinical findings, possible side effects, treatment availability, and differences from Lutetium-177.
Introduction
Actinium-225 PSMA therapy is an emerging targeted radiation approach currently being investigated for patients with metastatic castration-resistant prostate cancer (mCRPC). It combines Actinium-225 (Ac-225), a radioactive isotope, with a PSMA-targeting molecule that recognizes prostate-specific membrane antigen (PSMA), a protein commonly found on prostate cancer cells.
Early clinical observations have identified promising responses in some treated patients, including men whose cancer has continued to progress after previous therapies. Nevertheless, current research has not established whether this treatment provides a long-term survival benefit or offers a clear advantage over existing treatment options.
Patients who wish to consult prostate cancer specialists in Germany can contact Treatment in Germanyfor assistance with medical records and appointment coordination.
How Actinium-225 PSMA Therapy Targets Prostate Cancer
Actinium-225 PSMA therapy is classified as targeted alpha therapy. The treatment uses a molecule that attaches to PSMA and carries the radioactive isotope towards cancer cells expressing this protein.
Once administered, the compound moves through the bloodstream and can bind to cells with suitable PSMA expression. Actinium-225 then releases alpha particles, delivering radiation close to the targeted cells.
Alpha radiation has high energy but travels only a short distance through body tissue. This characteristic allows radiation to be concentrated within a limited area around the target. However, PSMA levels can differ between individual cancer lesions. Some areas may express substantial amounts of PSMA, whereas others may have lower expression or may not express the protein.
For this reason, the pattern of PSMA expression is an important consideration when assessing a patient's suitability for treatment.
Is Actinium-225 PSMA Therapy Approved for Routine Treatment?
Actinium-225 PSMA therapy has not been authorized for routine clinical use in the European Union. Its availability is currently associated with clinical trials and individual access arrangements permitted by the applicable national regulations.
Lutetium-177 PSMA therapy has an established regulatory position. In the European Union, it is authorized for a specified group of adults with progressive PSMA-positive metastatic castration-resistant prostate cancer following treatment with an androgen receptor pathway inhibitor, such as abiraterone or enzalutamide, and taxane chemotherapy.
Patients may potentially access Actinium-225 through:
-
Clinical trials evaluating the treatment.
-
Specialist centres participating in research programmes.
-
Compassionate-use or named-patient arrangements where legally allowed.
Access requirements vary between countries and treatment facilities. Eligibility depends on medical circumstances, applicable regulations and whether a centre can provide the therapy.
Clinical Studies Investigating Actinium-225 PSMA
Evidence about Actinium-225 PSMA therapy comes from different research approaches, including retrospective patient analyses, Phase 1 dose-finding studies and randomized clinical trials.
| Research category | What is being investigated? | What the findings can establish |
|---|---|---|
| Retrospective compassionate-use studies | Treatment outcomes among patients who have already received Actinium-225 | May identify response patterns and safety concerns but cannot reliably prove superiority |
| Phase 1 dose-finding studies | Dose levels, tolerability and early adverse effects | Provide information about safety and suitable dosing rather than definitive effectiveness |
| Randomized clinical trials | Comparison with standard care or another treatment approach | Can offer stronger evidence about relative benefits and risks |
The WARMTH Act includes a retrospective review of patients treated at seven different centres. These findings contribute to understanding real-world treatment experiences and potential safety issues.
However, retrospective studies have limitations. Patients are not randomly allocated to treatment groups, making it difficult to determine whether differences in outcomes are caused by the treatment itself or other patient-related factors.
PSMAcTION Phase 2/3 Research
The PSMAcTION Phase 2/3 trial is evaluating Actinium-225-PSMA-617 against standard care chosen by the treating physician. The study involves men whose prostate cancer has progressed following Lutetium-177 PSMA therapy.
At the time covered by the source information, the trial was listed as recruiting, and results had not been reported.
Early Clinical Findings and Treatment Response
Prostate-specific antigen (PSA) is commonly measured to monitor prostate cancer and assess changes during treatment. A reduction in PSA may indicate that the disease is responding, but it does not independently confirm that a treatment improves overall survival.
Researchers often use PSA50 as a response measure. It describes a reduction of at least 50% in a patient's PSA level compared with the baseline value.
The research reviews described in the available information reported the following observations:
-
Study review involving 26 patients: Seventeen patients achieved a PSA50 response following Lutetium-177 treatment. Median overall survival was reported at 7.7 months.
-
Study review involving 488 patients: Median overall survival was 15.5 months, with a median follow-up of nine months.
These results should be interpreted within the context of the individual studies. Their patient populations, research methods, sample sizes and follow-up periods were different. Therefore, the figures cannot be used as a direct treatment comparison or as proof that Actinium-225 extends survival.
Important factors affecting reported results include:
-
Patient characteristics and previous cancer treatments.
-
The number of participants included in each analysis.
-
Differences in study design and treatment procedures.
-
The length of time patients were followed.
More comprehensive clinical research is required to determine the actual benefits of Actinium-225 PSMA therapy.
Potential Side Effects of Actinium-225 PSMA Treatment
Targeted radiation treatment can also expose certain healthy tissues to radiation. Studies of Actinium-225 PSMA therapy have reported effects involving the salivary glands, blood cell counts and, less frequently, the kidneys.
Dry Mouth and Salivary Gland Exposure
Dry mouth is among the commonly reported adverse effects. This may happen because salivary glands can absorb PSMA-targeting compounds and receive radiation exposure during treatment.
Approximately two-thirds of patients in a larger review experienced dry mouth following the first treatment cycle. A smaller review generally described the symptoms as mild or moderate, although some patients stopped treatment.
Blood Count Changes
Actinium-225 PSMA therapy may affect bone marrow function and reduce the production of blood cells. The reported complications include:
-
Anemia: A decrease in red blood cells that may lead to weakness and fatigue.
-
Thrombocytopenia: Reduced platelet levels that can increase bruising or bleeding.
-
Leukopenia: Lower white blood cell counts that may affect the body's ability to fight infections.
Severe anemia was observed in approximately one-eighth of patients in the larger review and around one-third in the smaller review.
Patients with a history of several previous cancer treatments or reduced bone marrow reserve may have a higher risk of blood-related complications.
Kidney Function and Monitoring
Kidney-related effects have been reported less frequently than some other adverse effects. Even so, kidney function should be evaluated before treatment and monitored during the course of care.
Why Safety Findings Vary
Side effect rates differ between research studies because patient groups, treatment protocols and adverse event recording methods are not always the same.
Information about long-term safety is also limited because existing studies have not provided sufficiently extensive follow-up. Continued monitoring and additional research will be important for understanding possible longer-term effects.
Actinium-225 vs. Lutetium-177 PSMA Therapy
Both Actinium-225 and Lutetium-177 are used in treatments designed to target PSMA-positive prostate cancer cells. Their main distinction is the type of radiation each isotope produces.
| Feature | Actinium-225 | Lutetium-177 |
|---|---|---|
| Radiation type | Alpha particles | Beta particles |
| Energy delivery | High energy over a short tissue distance | Travels farther through tissue |
| Treatment availability | Investigational | EU-authorized for a specified indication |
| Clinical evidence | Early findings and ongoing research | More established clinical evidence |
| Treatment role | Being investigated for advanced prostate cancer | Has an established role in eligible patients |
Any visual comparison of these radiation types is conceptual and not to scale.
Does Actinium-225 Offer an Advantage Over Lutetium-177?
There is currently no definitive evidence showing that Actinium-225 is the better treatment for all patients.
Lutetium-177 has a more established clinical evidence base and an authorized indication for a specific patient population. Actinium-225 remains investigational, although early research has reported responses in some patients, including those whose disease progressed after Lutetium-177 therapy.
Researchers still need to determine whether switching to Actinium-225 can overcome resistance to previous PSMA-targeted treatment or produce a meaningful improvement in survival.
When considering either approach, specialists may review:
-
The current progression and extent of the cancer.
-
PSMA PET imaging results.
-
Previous treatments and their outcomes.
-
Blood counts and bone marrow function.
-
Kidney function and the patient's general medical condition.
The treatment decision should be individualized according to clinical findings and the available evidence.
Questions Patients Should Ask Their Specialist
Before considering Actinium-225 PSMA therapy, patients should discuss the treatment process, possible complications and access requirements with an experienced specialist.
The following questions can help prepare for that discussion:
-
Is Actinium-225 available through a clinical trial or another legally permitted access programme?
-
Do my PSMA PET scan results suggest that I could be eligible?
-
How might my previous treatments influence my suitability?
-
Which blood tests and kidney function checks are needed?
-
Will I need to travel for treatment, and what follow-up care will be required?
-
What symptoms, including fever, unusual bruising or bleeding, should I report?
-
What are the expected treatment costs, and are funding options available?
Discussing these issues before starting treatment can help patients understand the potential benefits, risks and practical requirements.
Future Prospects for Actinium-225 PSMA Therapy
Actinium-225 PSMA therapy remains an active area of prostate cancer research. Particular attention is being given to its potential role in patients with advanced disease who have already received other treatment options.
Early clinical observations have identified responses in selected patients, including some whose cancer progressed after Lutetium-177 PSMA therapy. However, early responses alone are not enough to demonstrate improved survival or establish a new standard of care.
Current evidence has not confirmed a definitive survival advantage for Actinium-225 or established it as a routine alternative to authorized prostate cancer treatments.
Larger, well-designed clinical trials with longer follow-up are needed to clarify its effectiveness, safety and appropriate place in prostate cancer management.
Until more conclusive evidence becomes available, patients should discuss this investigational treatment with a qualified specialist who can assess their medical history, PSMA imaging, previous therapies, blood counts, kidney function and overall health.